SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-1208
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Relationship Between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2011English

Capecitabine-Based Treatment of a Patient With a Novel DPYD Genotype and Complete Dihydropyrimidine Dehydrogenase Deficiency

International Journal of Cancer
Cancer ResearchOncology
2017English

Table 2: Haplotypes Constructed by Three SNPs in HBV-infected Individuals and Controls.

English

Different Effects of Apolipoprotein A5 SNPs and Haplotypes on Triglyceride Concentration in Three Ethnic Origins

Journal of Human Genetics
Genetics
2010English

MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients

PLoS ONE
Multidisciplinary
2013English

MicroRNA Expression and Outcome in Resected NSCLC--Letter

Cancer Research
Cancer ResearchOncology
2011English

Identification of Risk-Related Haplotypes With the Use of Multiple SNPs From Nuclear Families

American Journal of Human Genetics
Genetics
2007English

Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Table 2: Distribution of ITS Haplotypes and cpDNA Haplotypes in Two Hybrid Swarms.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy